TS11B: INTRODUCTION TO SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT
WEDNESDAY, JUNE 19 - THURSDAY, JUNE 20
H. James Harwood Jr., PhD, Founder and CEO, Delphi BioMedical Consultants, LLC
This 1.5-day lecture-based interactive seminar focuses on strategies for identifying drug discovery targets, discovering and characterizing small molecule hits, and developing structure-activity relationships to advance hits through lead optimization,
preclinical development, and clinical evaluation. Participants will learn the stages and processes required to advance programs from idea to clinic, through examples and case studies. This seminar is intended for scientists in either academia or industry
who would like to become more familiar with small molecule drug discovery and development.
2:30 pm - 5:30 pm Seminar Sessions
5:30 - 6:05 pm Networking Reception
7:15 am - 8:00 am Breakout Discussion Groups with Continental Breakfast
8:00 am - 4:00 pm Seminar Sessions
12:00 - 12:30 pm Lunch Provided
Exhibit Hall Refreshment Breaks also provided.
TOPICS TO BE DISCUSSED:
- Stages of drug discovery, development, and clinical evaluation
- Strategies for identifying key drug discovery targets
- Screening strategies for discovering and characterizing small molecule modulators
- Use of structure-based drug design to develop structure-activity relationships
- In vitro, in culture, and in vivo strategies for optimizing drug-like properties, efficacy and pharmacokinetics
- Strategies for selecting developmental candidates
- Requirements for advancing a developmental candidate to clinical trials
- Biomarkers – translation of efficacy in experimental animals to efficacy in humans
- Design of clinical trials – proof-of-concept efficacy studies
- Design of clinical trials – outcome efficacy studies
James Harwood Jr., PhD, Founder and CEO, Delphi BioMedical Consultants, LLC
Dr. Harwood is a former Principal Research Investigator at Pfizer. Currently, he is the Founder and Chief Consultant at Delphi BioMedical Consultants LLC, Adjunct Professor Department of Cell and Molecular Biology and Health Professions Advisory Committee
Member at the University of Rhode Island, and Adjunct Professor Department of Pathology at Wake Forest University. Jim brings more than 30-year experience in drug R&D in pharmaceutical industry especially in physiology and pharmacology of metabolic
and cardiovascular diseases.
Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment
breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the Training Seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the
seminar, but after these have been distributed, no additional books will be available.
Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because seminars
are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.